[{"orgOrder":0,"company":"Ethicon","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ethicon","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ethicon","sponsor":"OMRIX BIOPHARMACEUTICALS LTD","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Human Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ OMRIX Biopharmaceuticals Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ OMRIX Biopharmaceuticals Ltd"},{"orgOrder":0,"company":"Ethicon","sponsor":"Ethicon","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Ethicon","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Ethicon"},{"orgOrder":0,"company":"Ethicon","sponsor":"Ethicon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Ethicon \/ Ethicon","highestDevelopmentStatusID":"1","companyTruncated":"Ethicon \/ Ethicon"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Undisclosed","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Neurology","graph2":"Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"OMRIX BIOPHARMACEUTICALS LTD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ OMRIX Biopharmaceuticals Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Ethicon \/ OMRIX Biopharmaceuticals Ltd"},{"orgOrder":0,"company":"Ethicon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Fibrin Sealant","moa":"Fibrinogen \/ Thrombin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ethicon \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Ali Aminian","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Ali Aminian","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Ali Aminian"}]

Find Clinical Drug Pipeline Developments & Deals by Ethicon

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          January 31, 2025

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase IV

                          Sponsor : Ali Aminian

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Fibrin Sealant is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 21, 2017

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Evicel (Fibrin Sealant) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cerebrospinal Fluid Leak.

                          Product Name : Evicel

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 29, 2015

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Evicel (Fibrin Sealant) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cerebrospinal Fluid Otorrhea.

                          Product Name : Evicel

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 05, 2014

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Fibrin Sealant is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 28, 2014

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Evicel (Fibrin Sealant) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemorrhage.

                          Product Name : Evicel

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 28, 2014

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 24, 2014

                          Lead Product(s) : Thrombin

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Fibrin Sealant is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cardiovascular Diseases.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 20, 2014

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemostasis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 14, 2014

                          Lead Product(s) : Thrombin

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Johnson & Johnson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Fibrin Sealant is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemorrhage.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 25, 2013

                          Lead Product(s) : Fibrin Sealant

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank